2021
Pioneering work by grantee Ilyas Washington, PhD, leads to FDA "Breakthrough Therapy" designation for potential Stargardt disease treatment, with possibilities for treating dry AMD—two vision diseases that can lead to blindness.
“BrightFocus was the first major funder of my academic lab. They gave me the opportunity – and the confidence – to believe that I could someday stop someone from losing their sight.” – Dr. llyas Washington